National Institute of Allergy and Infectious Diseases Enabling and Advancing Technologies (NEAT)

Award Date 7/22/2024
Last Date To Order 7/21/2029
Shared Ceiling $1.1B
Contract Type
Master BPA
Predecessor
Not listed
Successors

The National Institute of Allergy and Infectious Diseases Enabling and Advancing Technologies (NEAT) Master Blanket Purchase Agreement (BPA) is designed to provide comprehensive information technology (IT) services to the National Institutes of Health, specifically supporting the National Institute of Allergy and Infectious Diseases (NIAID) and the Office of Cyber Infrastructure and Computational Biology (OCICB). This contract vehicle enables efficient procurement of essential technological services with a substantial shared ceiling of $1.1 billion, spanning a period from July 22, 2024, to July 21, 2029. The BPA is strategically structured to support the advanced computational and technological needs of critical public health research institutions, focusing on delivering specialized IT solutions that enhance scientific research capabilities.

Task orders under this BPA are likely to encompass a wide range of sophisticated IT services, including cyber infrastructure development, computational biology support, network management, and advanced technological consulting. While specific task order details are not provided, typical awards in similar NIH-focused vehicles range from $500,000 to $5 million, with durations typically spanning 12 to 36 months. Prime contractors for such vehicles often include large federal IT service providers with extensive experience in scientific and research computing environments, such as SAIC, Booz Allen Hamilton, and specialized technology integrators with deep expertise in federal health research technology. The BPA likely includes set-aside opportunities for small businesses, particularly those certified in categories like 8(a), HUBZone, or service-disabled veteran-owned small businesses, reflecting standard federal procurement diversity goals. Performance locations would predominantly be in the Maryland and Washington, D.C. metropolitan areas, closely aligned with NIH's primary research campuses.

Generated 1/16/25, 12:20 AM